9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines
Key Takeaways
- Unit-dose packaging encloses a single dose of medication ready for administration, minimizing bedside measurement errors, enhancing inventory tracking, and enabling the return of unadministered sealed doses.
- Under USP <795> and FDA repackaging guidelines, the Beyond-Use Date (BUD) for non-sterile solid oral unit-dose repackaged drugs shall not exceed EITHER 6 months from the date of repackaging OR 25% of the remaining manufacturer expiration date, WHICHEVER IS SHORTER.
- The assigned BUD can never exceed the manufacturer's original expiration date under any circumstances.
- Every unit-dose package must display mandatory label elements: generic/brand name, strength, dosage form, repackager lot number, BUD, manufacturer name, special storage requirements, and auxiliary labels.
- A comprehensive Repackaging Control Log must be maintained for every batch, documenting manufacturer lot, original expiration, assigned internal lot, assigned BUD, quantity packaged, packaging materials, and technician/pharmacist verification signatures.
Unit-Dose Repackaging Standards and USP <795> BUD Guidelines
Core Verification Rule: Unit-dose repackaging transforms bulk commercial stock into individually sealed, barcoded single doses ready for patient administration. The verifying technician must confirm that every unit-dose blister or cup contains all required regulatory label elements, an accurate internal lot number, and an assigned Beyond-Use Date (BUD) calculated strictly in compliance with the USP <795> 6-Month or 25% Rule.
In acute care hospitals, health systems, and long-term care (LTC) facilities, the unit-dose drug distribution system represents the clinical gold standard for patient safety. Rather than dispensing multi-dose bulk bottles to patient care areas, the pharmacy prepares and distributes medications in individual unit-of-use packages containing the exact dose ordered for a single administration time.
1. Principles and Modalities of Unit-Dose Packaging
Unit-dose packaging provides multiple clinical and operational safeguards:
- Error Reduction: Eliminates the need for nursing staff to measure liquids, count tablets, or manipulate dosage forms at the bedside.
- Contamination Prevention: Protects individual dosage units from atmospheric moisture, light, air, and microbial contamination until the moment of consumption.
- Inventory & Waste Control: Unopened, undamaged unit-dose packages returned from nursing units can be safely restocked into pharmacy inventory (unlike opened bulk patient vials).
- Bedside Barcode Verification (BCMA): Enables nurses to scan both the patient's ID wristband and the unit-dose barcode to achieve five-rights verification at the bedside.
Common Packaging Formats
| Packaging Modality | Clinical Setting | Typical Dosage Forms | Packaging Materials / Equipment |
|---|---|---|---|
| Blister Cards (Unit-Dose Blisters) | Inpatient Hospitals, LTC | Oral solid tablets, capsules | PVC / Aclar thermoform blisters heat-sealed with foil backing (USP Class A or B barrier) |
| Unit-Dose Liquid Cups | Inpatient Hospitals | Oral solutions, suspensions, elixirs | Polyethylene / polypropylene cups sealed with peelable aluminum foil lid |
| Strip Packaging (Pouches) | Centralized Fill, LTC | Solid oral solids, multi-med compliance | Automated high-speed packagers (Pacmed, Parata) producing continuous cellophane/poly pouches |
| Oral Syringes (Unit-Dose) | Pediatric & Adult Inpatient | Oral liquids, critical titrations | Amber or clear oral dispensers with tamper-evident tip caps (never accepting IV luer needles) |
| Bingo Cards / Multi-Dose Cards | Skilled Nursing Facilities | 30-day or 31-day blister cards | Multi-cavity blister sheets with cold-seal or heat-seal foil backing |
2. USP <795> and FDA Beyond-Use Date (BUD) Guidelines
A fundamental concept tested on the TPV exam is the regulatory and scientific distinction between a manufacturer's Expiration Date and a pharmacy's Beyond-Use Date (BUD):
- Manufacturer Expiration Date: Determined by the pharmaceutical manufacturer through extensive stability, sterility, and degradation testing in the original commercial container closure. It represents the date until which the drug is guaranteed to maintain full potency, chemical purity, and physical stability.
- Beyond-Use Date (BUD): Assigned by the pharmacy or repackager when a drug product is removed from its original manufacturer packaging and transferred into a new container closure (e.g., unit-dose blister, oral syringe, or prescription vial). It reflects the shortened timeframe during which the repackaged preparation can be safely administered.
The "6-Month or 25% Rule" for Non-Sterile Solid Oral Repackaging
According to USP General Chapter <795> (Pharmaceutical Compounding — Nonsterile Preparations) and FDA Repackaging Guidance for Solid Oral Dosage Forms, when non-sterile solid oral dosage forms (tablets, capsules) are repackaged into unit-dose containers using USP Class A or Class B packaging materials, the assigned BUD shall not exceed:
[!IMPORTANT] The USP <795> Non-Sterile Repackaging BUD Rule: The assigned Beyond-Use Date (BUD) shall be the SHORTER of:
- 6 months (180 days) from the date of repackaging, OR
- 25% of the remaining time between the repackaging date and the manufacturer's original expiration date.
Condition: In no circumstance may the assigned BUD exceed the manufacturer's original expiration date.
BUD = Date of Repackaging + MIN [ 6 Months, (0.25 × Remaining Time to Mfg Expiration) ]
3. Step-by-Step Mathematical BUD Calculations
To determine the exact BUD, technicians must follow a systematic 4-step calculation sequence:
- Calculate Remaining Shelf Life: Count the total months (or days) from the date of repackaging to the manufacturer's expiration date.
- Calculate 25% of Remaining Time: Multiply the remaining shelf life by 0.25 (or divide by 4).
- Compare Against 6-Month Threshold: Compare the 25% calculated value against 6 months.
- Assign the Shorter Period: Add the shorter duration to the repackaging date to establish the final BUD.
Calculation Scenarios
Scenario 1: Manufacturer Expiration is 12 Months Away
- Repackaging Date: January 1, 2026
- Manufacturer Expiration: January 1, 2027 (12 months remaining)
- Step 1: Remaining shelf life = $12\text{ months}$
- Step 2: $25% \times 12\text{ months} = 3\text{ months}$
- Step 3: Compare 3 months vs. 6 months $\rightarrow$ $3\text{ months} < 6\text{ months}$
- Step 4: Assigned BUD = January 1, 2026 + 3 months = April 1, 2026
Scenario 2: Manufacturer Expiration is 36 Months Away
- Repackaging Date: March 1, 2026
- Manufacturer Expiration: March 1, 2029 (36 months remaining)
- Step 1: Remaining shelf life = $36\text{ months}$
- Step 2: $25% \times 36\text{ months} = 9\text{ months}$
- Step 3: Compare 9 months vs. 6 months $\rightarrow$ $6\text{ months} < 9\text{ months}$
- Step 4: Assigned BUD = March 1, 2026 + 6 months = September 1, 2026 (Capped at 6 months!)
Scenario 3: Manufacturer Expiration is 4 Months Away
- Repackaging Date: May 1, 2026
- Manufacturer Expiration: September 1, 2026 (4 months remaining)
- Step 1: Remaining shelf life = $4\text{ months}$
- Step 2: $25% \times 4\text{ months} = 1\text{ month}$
- Step 3: Compare 1 month vs. 6 months $\rightarrow$ $1\text{ month} < 6\text{ months}$
- Step 4: Assigned BUD = May 1, 2026 + 1 month = June 1, 2026
Scenario 4: Manufacturer Expiration is 24 Months Away
- Repackaging Date: July 15, 2026
- Manufacturer Expiration: July 15, 2028 (24 months remaining)
- Step 1: Remaining shelf life = $24\text{ months}$
- Step 2: $25% \times 24\text{ months} = 6\text{ months}$
- Step 3: Compare 6 months vs. 6 months $\rightarrow$ Equal (6 months)
- Step 4: Assigned BUD = July 15, 2026 + 6 months = January 15, 2027
4. Required Unit-Dose Label Elements
Because unit-dose packages are small, every square millimeter of label space is regulated. The FDA, USP, and State Boards of Pharmacy mandate that every individual unit-dose package contain specific minimum data points:
┌────────────────────────────────────────────────────────┐
│ METOPROLOL TARTRATE [Rx Only] │
│ 50 mg Film-Coated Tablet │
│ Mfg: Teva Pharmaceuticals │
│ Repackaged Lot: PKG-2026-0829 │
│ BUD: 02/28/2027 Store at 20°-25°C (Excursions) │
│ ║▌║█║▌║▌║███║▌║ NDC: 00093-0123-01 │
└────────────────────────────────────────────────────────┘
Mandatory Unit-Dose Labeling Checklist
- Generic Name: Non-proprietary generic drug name (prominently displayed; e.g., Metoprolol Tartrate).
- Brand Name: Proprietary trade name if applicable (e.g., Lopressor), especially if brand-specific.
- Strength and Concentration: Numerical strength and unit of measure (e.g., 50 mg, 250 mg/5 mL).
- Dosage Form: Specific physical form (e.g., Tablet, Capsule, Oral Solution, Extended-Release Tablet).
- Assigned Beyond-Use Date (BUD): Clear date beyond which the dose cannot be administered.
- Pharmacy / Repackager Lot Number: Internal control lot number linking the package back to the master repackaging log.
- Manufacturer Name: Name of the original commercial manufacturer (or repackaging facility name).
- Special Storage Conditions: Specific temperature or environmental warnings (e.g., Refrigerate 2°–8°C, Protect from Light, Do Not Freeze).
- Auxiliary Warning Labels: Required cautionary statements (e.g., Chemotherapy / Hazardous Drug, Do Not Crush, Shake Well Before Using).
- Machine-Readable Barcode: Linear (Code 128) or 2D Data Matrix barcode encoding NDC, internal lot, and BUD for bedside scanning.
5. Repackaging Control Logs & Quality Audit Trails
Maintaining a meticulous Repackaging Control Log (Master Batch Record) is legally required. In the event of a commercial manufacturer recall or packaging integrity failure, the pharmacy must be able to instantly trace every repackaged unit back to its original source.
| Log Sheet Field | Operational Requirement & Regulatory Purpose |
|---|---|
| Repackaging Date | Date the batch was packaged; establishes baseline for BUD calculation. |
| Drug Generic & Brand Name | Complete chemical name, salt form, and brand equivalent. |
| Strength & Dosage Form | Exact potency and physical formulation. |
| Commercial Manufacturer | Name of the original drug manufacturer. |
| Manufacturer Original Lot # | Source lot number printed on the bulk manufacturer stock bottle. |
| Manufacturer Expiration Date | Original expiration date from bulk container. |
| Assigned Internal Lot / Batch # | Unique serial control number assigned by the pharmacy (e.g., LOT-2026-0829-01). |
| Assigned Beyond-Use Date (BUD) | Calculated BUD accompanied by calculation rationale. |
| Quantity Repackaged | Total count of unit doses produced in the batch (e.g., 500 unit-dose tablets). |
| Packaging Material & Equipment | Class of blister foil, cup type, seal temperature, and machine ID used. |
| Technician Signature / Initials | Signature of the packaging technician who prepared the batch. |
| Pharmacist / TPV Verification Sign-off | Signature of the verifying professional who inspected the batch and approved release. |
[!CAUTION] Recall Traceability Protocol: If the FDA announces a Class I recall for a specific manufacturer lot number, the pharmacy must query its Repackaging Control Logs to identify every internal lot number linked to that bulk lot. Verifying technicians must pull all matching unit doses from automated dispensing cabinets, floor stock, and cart fills immediately.
On October 1, 2026, an institutional pharmacy technician repackages bulk Furosemide 40 mg tablets into unit-dose blister packages. The manufacturer's bulk stock bottle displays an expiration date of October 1, 2027 (exactly 12 months remaining). In accordance with USP <795> and FDA non-sterile repackaging guidelines, what is the maximum Beyond-Use Date (BUD) that can be assigned to this repackaged batch?
Which of the following data elements is MANDATORY on an individual unit-dose blister package label under FDA and USP standards?
On February 1, 2026, a technician is preparing unit-dose blister packs of Metformin 500 mg tablets. The bulk stock bottle carries a manufacturer expiration date of February 1, 2029 (36 months remaining). What is the maximum allowable Beyond-Use Date (BUD) for this repackaged medication?
The FDA issues a Class I nationwide recall for a specific manufacturer lot of Levothyroxine tablets due to subpotency. During product verification, how does the pharmacy locate any unit-dose blister packs that were repackaged from the recalled bulk stock?